Literature DB >> 29375870

Orbital plasmablastic lymphoma.

Edward Bloch1, Fiona Robinson1.   

Abstract

Plasmablastic lymphoma is an unusual and aggressive form of diffuse large B-cell lymphoma, which arises more commonly within the oronasal mucosa. It should be considered as a differential diagnosis for rapidly growing periorbital lesions, particularly in the context of HIV positivity.

Entities:  

Keywords:  HIV; orbital tumors; plasmablastic lymphoma

Year:  2017        PMID: 29375870      PMCID: PMC5771934          DOI: 10.1002/ccr3.1281

Source DB:  PubMed          Journal:  Clin Case Rep        ISSN: 2050-0904


Case Presentation

A 45‐year‐old HIV‐positive man presented with a 2‐week history of swelling of the right lower eyelid. Magnetic resonance imaging revealed a plaque of enhancing soft tissue at the inferolateral border of the orbit (A). Incisional biopsy showed skin (B) with normal epidermis and Grenz zone (star), overlying an infiltrate of large atypical lymphoid cells (C) with mitotic figures (arrow). On immunohistochemical staining, lymphocytes were positive for MUM1 (D), CD38 (E), but negative for CD20. Ki67 proliferative index (F) and EBER in situ hybridization for Epstein–Barr virus (G) were strongly positive, signifying plasmablastic lymphoma (Fig. 1).
Figure 1

Magnetic resonance imaging and incisional biopsy histopathology

Magnetic resonance imaging and incisional biopsy histopathology This neoplasm, a rare and aggressive subtype of DLBCL, has more frequently been described originating from the oral and sinonasal of HIV‐positive males 1, 2, but has also been reported in immunocompetent patients 2, 3, 4. In this case, the primary lesion appears to be within the orbital mucosa. There is no standardized therapy and most published cases included systemic treatment with an individualized intensive chemotherapy regime similar to that of other lymphomas 1, 2. Prognosis is poor with an overall median survival of 8 months 5. Our patient shows some improvement at 3 months postdiagnosis, having been commenced on cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisolone (CHOP protocol) chemotherapy.

Authorship

EB and FR: contributed to the writing and approval of the final manuscript.
  5 in total

Review 1.  The biology and treatment of plasmablastic lymphoma.

Authors:  Jorge J Castillo; Michele Bibas; Roberto N Miranda
Journal:  Blood       Date:  2015-01-30       Impact factor: 22.113

2.  Orbital plasmablastic lymphoma--comparison of a newly reported entity with diffuse large B-cell lymphoma of the orbit.

Authors:  Ana M S Morley; David H Verity; George Meligonis; Geoffrey E Rose
Journal:  Orbit       Date:  2009

3.  Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases.

Authors:  Julie Morscio; Daan Dierickx; Jan Nijs; Gregor Verhoef; Emilie Bittoun; Xanne Vanoeteren; Iwona Wlodarska; Xavier Sagaert; Thomas Tousseyn
Journal:  Am J Surg Pathol       Date:  2014-07       Impact factor: 6.394

4.  Orbital plasmablastic lymphoma: a clinico-pathological correlation of a rare disease and review of literature.

Authors:  Kaustubh Mulay; Mohammad Javed Ali; Vijay Anand Reddy; Santosh G Honavar
Journal:  Clin Ophthalmol       Date:  2012-12-11

5.  Human immunodeficiency virus-negative plasmablastic lymphoma: a comprehensive analysis of 114 cases.

Authors:  Min Liu; Bailong Liu; Bin Liu; Qiang Wang; Lijuan Ding; Chengcheng Xia; Lihua Dong
Journal:  Oncol Rep       Date:  2015-02-17       Impact factor: 3.906

  5 in total
  1 in total

Review 1.  Heterogeneity in the diagnosis of plasmablastic lymphoma, plasmablastic myeloma, and plasmablastic neoplasm: a scoping review.

Authors:  Hirotaka Mori; Masahiko Fukatsu; Hiroshi Ohkawara; Yuka Oka; Yuki Kataoka; Shunsuke Taito; Takayuki Ikezoe
Journal:  Int J Hematol       Date:  2021-08-30       Impact factor: 2.490

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.